This Sources Sought opportunity from Department Of Health And Human Services was posted on July 17, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Generic Drug Pathway Curriculum: From ANDA Submission to Global Reliance

Closed

OC-2026-135574Federal

Submission Closed07/28/2026, 04:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The U.S. Food and Drug Administration’s Office of Acquisitions and Grants Services is conducting market research to identify qualified vendors capable of delivering the Global Abbreviated New Drug Application (ANDA) Training Program, with a focus on developing and delivering a comprehensive curriculum covering the generic drug pathway from ANDA submission to global reliance. This notice is strictly a sources sought announcement under FAR Part 10, meant solely for planning and market intelligence purposes, and does not constitute a solicitation, commitment, or obligation to award a contract or compensate respondents. The anticipated contract, if pursued, would have a five-year performance period from September 15, 2026, through September 14, 2031, including a base year and four optional years. Interested parties are requested to submit a completed Vendor Feedback Form, tracked comments on the Draft Statement of Work and Draft Global ANDA Training - Generic Drug Curriculum in MS Word format, and a Capability Statement, all sent via email to Lawrence Edelmann by 12:00 p.m. Eastern Time on July 28, 2026. Responses will inform the development of a potential future solicitation, and the government reserves the right to follow up with respondents for additional details without providing feedback to all submitters. The NAICS code associated with this effort is 61143, and the primary point of contact is located at the FDA’s office in Rockville, Maryland, with performance expected in Silver Spring, Maryland.

General Info

FDA seeks vendors for five-year Global ANDA Training Program starting September 2026, with submissions due July 28, 2026.

Agency

Department Of Health And Human Services → FDA Office Of Acq Grant SvcsView Agency

NAICS

61143

Place of Performance

Silver Spring, MD, 20993, USA

Set-Aside

NONE

Documents

(3)

FDA Generic Drug Pathway Curriculum Vendor Feedback Form OC-2026-135574

DOCX•sources-sought

Draft SOW Global ANDA Training Program OC-2026-135574

DOCX•sow

FDA Generic Drug Pathway Curriculum Training

DOCX•training-curriculum

AI Contract Breakdown

Uniform Contract Format

Timeline

PhaseClosed

PostedJul 17

Sources Sought

Response DeadlineJul 28

Deadline has passed

Submission Closed

07/28/2026, 04:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → FDA Office Of Acq Grant Svcs

Contacts1 person available

OfficeRockville, MD, 20852, USA

Organization / Agency

Department Of Health And Human Services → FDA Office Of Acq Grant Svcs

View Agency Profile

Office AddressRockville, MD, 20852, USA

Contacts

Lawrence Edelmann

contact@example.gov

Full Description

The U.S. Food and Drug Administration's (FDA), Office of Acquisitions and Grants Services (OAGS), is conducting market research for obtaining Global Abbreviated New Drug Application (ANDA) Training Program services.

THIS IS A SOURCES SOUGHT NOTICE (SSN) ONLY. This SSN is being issued in accordance with Federal Acquisition Regulation (FAR) Part 10, Market Research. It is for information, planning, and market research purposes only and is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. The Government reserves the right to contact any of the respondents after the submission deadline if additional information is required.

The purpose of this SSN is to identify and gain knowledge of potential business sources and small business sources that are capable of providing the full range of services described in this SSN and the attached Draft Statement of Work (SOW). Responses to this SSN will be utilized for a potential solicitation for an anticipated stand-alone contract for the Global Abbreviated New Drug Application (ANDA) Training Program. The anticipated period of performance for this contract is September 15, 2026 through September 14, 2031 (base year, plus four (4) option years.

Requested Information

Interested parties are highly encouraged to respond to this SSN by providing the following information in their response:

Completed Vendor Feedback Form – See attached Vendor Feedback Form
If applicable, tracked changes/comments on Draft SOW and Draft Generic Drug Curriculum in MS Word format – See attached Draft SOW and attached Draft Global ANDA Training - Generic Drug Curriculum.
Capability Statement

Responses shall be submitted via email with the subject line "Sources Sought Notice - FDA SSN: OC-2026-135574” to the Contract Specialist, Lawrence Edelmann (lawrence.edelmann@fda.hhs.gov), no later than 12:00pm (Eastern) on July 28, 2026.

Attachments